NEW YORK, June 9 /PRNewswire/ --
Monday, June 9th, 2008
1:00 PM - 1:15 PM ET
Downlink Freq: 4180 H
NEWS: LARGE, LONG-TERM VETERANS AFFAIRS DIABETES TRIAL (VADT) REVEALS
IMPORTANT CARDIOVASCULAR SAFETY NEWS ON AVANDIA
FORMAT: B-roll and Sound bites
ADDITIONAL RESOURCES: Video, hard copy requests, downloadable MPEG2, contact information and more available at http://www.prnewswire.com/broadcast/33475/press.html
At the 68th Scientific Sessions of the American Diabetes Association in San Francisco, CA, several studies were presented evaluating the impact of blood sugar control to reduce diabetes-related complications in patients.
VADT (Veterans Affairs Diabetes Trial), a large, long-term and independent outcomes study, evaluated whether intensive versus standard blood sugar control can reduce the incidence of major cardiovascular (CV) events associated with diabetes including heart attack, congestive heart failure and CV death.
According to news announced by the ADA, AVANDIA(R) (rosiglitazone maleate) was used in a majority of patients in the study and was not associated with increased deaths. These data are consistent with results from other long-term studies with AVANDIA.
The primary result of VADT did not show that intensive blood sugar
control (HbA1c levels below 7%) had a statistically significant effect on
reducing major CV events associated with diabetes. However, it was found
that there was a favorable trend in reducing all CV events, except CV
death, among the patients in the intensive arm. While the VADT did not meet
its primary endpoint, it is critical that these results do not detract from
what is already known about the benefits of long-term blood sugar control
on other serious and potentially life-threatening complications of
diabetes, such as kidney failure, blindness and amputation. VADT is an
independent study sponsored by the Department of Veterans Affairs.
-- Dr. Farhad Zangeneh, MD, FACP, FACE, assistant clinical professor of
medicine at the George Washington University in Washington, DC and
medical director at the Endocrine, Diabetes & Osteoporosis Clinic in
-- Type 2 diabetes patients
B-ROLL INCLUDES: **Physician footage**Footage of type 2 diabetes patients
**Footage of AVANDIA product**
VIDEO PROVIDED BY: GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved